Add as a preferred source on GoogleEton Lifts 2026 Revenue Outlook Above $175 Million, Targets LIBERVANT Launch
Third-quarter 2026 revenue rose 158% year over year to $57.9 million. Eton expects adjusted EBITDA margin above 40%.
Eton Pharmaceuticals now projects revenue above $175 million for 2026 and an adjusted EBITDA margin exceeding 40%. It is targeting an April 2027 launch for LIBERVANT.
The company recorded third-quarter 2026 revenue of $57.9 million, up 158% year over year. “It was another outstanding quarter for Eton with record revenue, significant margin expansion and strong cash flow generation,” President, CEO and Director Sean Brynjelsen said.
LIBERVANT is a diazepam buccal film for treating seizures. Eton's exclusive license agreement with Aquestive Therapeutics covers the drug. The planned launch depends on final FDA approval and resolution of applicable exclusivity restrictions.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.